Visus Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 36

Employees

  • Latest Deal Type
  • M&A

Visus Therapeutics General Information

Description

Developer of ophthalmic therapies intended to improve vision for people around the world. The company offers presbyopia-correcting eye drops with the potential to last hours and ophthalmic product candidates include applications in ocular surface disease, glaucoma, and age-related macular degeneration, enabling patients to correct the loss of near vision associated with presbyopia.

Contact Information

Website
www.visustx.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 2 Nickerson Street
  • Suite 101
  • Seattle, WA 98109
  • United States
+1 (800)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 2 Nickerson Street
  • Suite 101
  • Seattle, WA 98109
  • United States
+1 (800)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Visus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 12-Dec-2024 Completed Generating Revenue
4. Early Stage VC (Series B2) 01-Jun-2023 Completed Clinical Trials - Phase 3
3. Secondary Transaction - Private Completed Clinical Trials - Phase 3
2. Early Stage VC (Series A2) 10-Aug-2021 $20M $56M Completed Clinical Trials - Phase 3
1. Early Stage VC (Series A) 09-Mar-2021 $36M $36M Completed Clinical Trials - Phase 3
To view Visus Therapeutics’s complete valuation and funding history, request access »

Visus Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-2
Series A-1
To view Visus Therapeutics’s complete cap table history, request access »

Visus Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of ophthalmic therapies intended to improve vision for people around the world. The company offers presbyopia-
Drug Discovery
Seattle, WA
36 As of 2024

Ann Arbor, MI
 

Durham, NC
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Visus Therapeutics Competitors (4)

One of Visus Therapeutics’s 4 competitors is ONL Therapeutics, a Venture Capital-Backed company based in Ann Arbor, MI.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ONL Therapeutics Venture Capital-Backed Ann Arbor, MI
Opus Genetics Formerly VC-backed Durham, NC
Orasis Pharmaceuticals Venture Capital-Backed Ponte Vedra Beach, FL
TearClear Venture Capital-Backed Princeton, NJ
To view Visus Therapeutics’s complete competitors history, request access »

Visus Therapeutics Patents

Visus Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025010288-A2 Hyaluronic acid based drug delivery systems Inactive 03-Jul-2023
WO-2025010288-A3 Hyaluronic acid based drug delivery systems Inactive 03-Jul-2023
AU-2024303954-A1 Synthesis of 2-(carbamoyloxy)-n,n,n-trimethylethan-1-aminium salts Pending 16-Jun-2023
EP-4727533-A2 Synthesis of 2-(carbamoyloxy)-n,n,n-trimethylethan-1-aminium salts Pending 16-Jun-2023
WO-2024259258-A2 Synthesis of 2-(carbamoyloxy)-n,n,n-trimethylethan-1-aminium salts Inactive 16-Jun-2023 C07D233/56
To view Visus Therapeutics’s complete patent history, request access »

Visus Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Visus Therapeutics Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
EQT Life Sciences Venture Capital Minority
Gershon Capital Venture Capital Minority
Johnson & Johnson JJDC Corporate Venture Capital Minority
Planet Innovation PE-Backed Company Minority
Qima Ventures Impact Investing Minority
You’re viewing 5 of 9 investors. Get the full list »

Visus Therapeutics Acquisitions (1)

Visus Therapeutics’s most recent deal was a Merger/Acquisition with ViewPoint Therapeutics. The deal was made on 28-Jul-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ViewPoint Therapeutics 28-Jul-2022 Merger/Acquisition Drug Discovery
To view Visus Therapeutics’s complete acquisitions history, request access »

Visus Therapeutics FAQs

  • When was Visus Therapeutics founded?

    Visus Therapeutics was founded in 2019.

  • Where is Visus Therapeutics headquartered?

    Visus Therapeutics is headquartered in Seattle, WA.

  • What is the size of Visus Therapeutics?

    Visus Therapeutics has 36 total employees.

  • What industry is Visus Therapeutics in?

    Visus Therapeutics’s primary industry is Drug Discovery.

  • Is Visus Therapeutics a private or public company?

    Visus Therapeutics is a Private company.

  • What is Visus Therapeutics’s current revenue?

    The current revenue for Visus Therapeutics is .

  • How much funding has Visus Therapeutics raised over time?

    Visus Therapeutics has raised $56M.

  • Who are Visus Therapeutics’s investors?

    EQT Life Sciences, Gershon Capital, Johnson & Johnson JJDC, Planet Innovation, and Qima Ventures are 5 of 9 investors who have invested in Visus Therapeutics.

  • Who are Visus Therapeutics’s competitors?

    ONL Therapeutics, Opus Genetics, Orasis Pharmaceuticals, and TearClear are competitors of Visus Therapeutics.

  • When was Visus Therapeutics acquired?

    Visus Therapeutics was acquired on 12-Dec-2024.

  • Who acquired Visus Therapeutics?

    Visus Therapeutics was acquired by Tenpoint Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process